Literature DB >> 16731046

Stable gammaretroviral vector expression during embryonic stem cell-derived in vitro hematopoietic development.

Ali Ramezani1, Teresa S Hawley, Robert G Hawley.   

Abstract

Unlike conventional gammaretroviral vectors, the murine stem cell virus (MSCV) can efficiently express transgenes in undifferentiated embryonic stem cells (ESCs). However, a dramatic extinction of expression is observed when ESCs are subjected to in vitro hematopoietic differentiation. Here we report the construction of a self-inactivating vector from MSCV, MSinSB, which transmits an intron embedded within the internal transgene cassette to transduced cells. The internal transgene transcriptional unit in MSinSB comprises the composite cytomegalovirus immediate early enhancer-chicken beta-actin promoter and associated 5' splice site positioned upstream of the natural 3' splice site of the gammaretroviral envelope gene, and is configured such that the transgene translational initiation sequence is coincident with the envelope ATG. MSinSB could be produced at titers approaching 10(6) transducing units/ml and directed higher levels of transgene expression in ESCs than a splicing-optimized MSCV-derived vector, MSGV1. Moreover, when transduced ESCs were differentiated into hematopoietic cells in vitro, MSinSB remained transcriptionally active in greater than 90% of the cells, whereas MSGV1 expression was almost completely shut off. Persistent high-level expression of the MSinSB gammaretroviral vector was also demonstrated in murine bone marrow transplant recipients and following in vitro myelomonocytic differentiation of human CD34(+) cord blood stem/progenitor cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16731046      PMCID: PMC2389876          DOI: 10.1016/j.ymthe.2006.04.005

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  49 in total

Review 1.  Silencing and variegation of gammaretrovirus and lentivirus vectors.

Authors:  James Ellis
Journal:  Hum Gene Ther       Date:  2005-11       Impact factor: 5.695

Review 2.  Embryonic stem cell differentiation: emergence of a new era in biology and medicine.

Authors:  Gordon Keller
Journal:  Genes Dev       Date:  2005-05-15       Impact factor: 11.361

Review 3.  Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors.

Authors:  Christopher Baum; Olga Kustikova; Ute Modlich; Zhixiong Li; Boris Fehse
Journal:  Hum Gene Ther       Date:  2006-03       Impact factor: 5.695

4.  Host cis-mediated extinction of a retrovirus permissive for expression in embryonal stem cells during differentiation.

Authors:  C Laker; J Meyer; A Schopen; J Friel; C Heberlein; W Ostertag; C Stocking
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

5.  Bypass of senescence, immortalization, and transformation of human hematopoietic progenitor cells.

Authors:  Sergey S Akimov; Ali Ramezani; Teresa S Hawley; Robert G Hawley
Journal:  Stem Cells       Date:  2005-09-06       Impact factor: 6.277

6.  R-region cDNA inserts in retroviral vectors are compatible with virus replication and high-level protein synthesis from the insert.

Authors:  M A Adam; W R Osborne; A D Miller
Journal:  Hum Gene Ther       Date:  1995-09       Impact factor: 5.695

7.  Amelioration of retroviral vector silencing in locus control region beta-globin-transgenic mice and transduced F9 embryonic cells.

Authors:  C S Osborne; P Pasceri; R Singal; T Sukonnik; G D Ginder; J Ellis
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

8.  Self-inactivating lentiviral vectors with U3 and U5 modifications.

Authors:  T Iwakuma; Y Cui; L J Chang
Journal:  Virology       Date:  1999-08-15       Impact factor: 3.616

9.  Correction of murine hemophilia A by hematopoietic stem cell gene therapy.

Authors:  Morvarid Moayeri; Teresa S Hawley; Robert G Hawley
Journal:  Mol Ther       Date:  2005-10-12       Impact factor: 11.454

10.  Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.

Authors:  Marybeth S Hughes; Yik Y L Yu; Mark E Dudley; Zhili Zheng; Paul F Robbins; Yong Li; John Wunderlich; Robert G Hawley; Morvarid Moayeri; Steven A Rosenberg; Richard A Morgan
Journal:  Hum Gene Ther       Date:  2005-04       Impact factor: 5.695

View more
  9 in total

1.  Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator.

Authors:  Chang Long Li; Ding Xiong; George Stamatoyannopoulos; David W Emery
Journal:  Mol Ther       Date:  2009-02-24       Impact factor: 11.454

2.  Reducing the genotoxic potential of retroviral vectors.

Authors:  Ali Ramezani; Teresa S Hawley; Robert G Hawley
Journal:  Methods Mol Biol       Date:  2008

Review 3.  The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors.

Authors:  David W Emery
Journal:  Hum Gene Ther       Date:  2011-03-25       Impact factor: 5.695

4.  Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells.

Authors:  D Hoffmann; J W Schott; F K Geis; L Lange; F-J Müller; D Lenz; D Zychlinski; D Steinemann; M Morgan; T Moritz; A Schambach
Journal:  Gene Ther       Date:  2017-04-20       Impact factor: 5.250

5.  Strategies to insulate lentiviral vector-expressed transgenes.

Authors:  Ali Ramezani; Robert G Hawley
Journal:  Methods Mol Biol       Date:  2010

6.  Combinatorial incorporation of enhancer-blocking components of the chicken beta-globin 5'HS4 and human T-cell receptor alpha/delta BEAD-1 insulators in self-inactivating retroviral vectors reduces their genotoxic potential.

Authors:  Ali Ramezani; Teresa S Hawley; Robert G Hawley
Journal:  Stem Cells       Date:  2008-09-11       Impact factor: 6.277

7.  Correction of murine hemophilia A following nonmyeloablative transplantation of hematopoietic stem cells engineered to encode an enhanced human factor VIII variant using a safety-augmented retroviral vector.

Authors:  Ali Ramezani; Robert G Hawley
Journal:  Blood       Date:  2009-05-21       Impact factor: 22.113

8.  Optimization of methods for the genetic modification of human T cells.

Authors:  Mahmood Y Bilal; Aldo Vacaflores; Jon Cd Houtman
Journal:  Immunol Cell Biol       Date:  2015-06-01       Impact factor: 5.126

Review 9.  Development of gene therapy: potential in severe combined immunodeficiency due to adenosine deaminase deficiency.

Authors:  Claudia A Montiel-Equihua; Adrian J Thrasher; H Bobby Gaspar
Journal:  Stem Cells Cloning       Date:  2009-12-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.